

**Iowa Medicaid Pharmaceutical and Therapeutics Committee
Minutes**

Date: November 21, 2024

Chairperson: Jason Kruse

Time: 9:31 a.m. to 1:42 p.m.

Location: Grimes State Office Building Room B100, 400 E 14th Street, Des Moines, IA 50319

Committee Members Present: Jason Kruse, D.O.; Lacey Ferguson, Pharm.D.; Rachel Kinn, Pharm.D. (via Zoom); Tricia McComb, R.N. (via Zoom); Dawn Schissel, M.D.; Fadi Yacoub, M.D.; and Jennifer Doudna, Pharm.D., R.Ph. (Vacancies July 2023: 1 Physician Assistant)

Committee Members Absent: Charles Wadle, D.O.

Iowa DHHS Staff Present: Abby Cate, Pharm.D., Pharmacy Consultant; and Darian Forcier, Pharmacy Administrative Support.

Iowa Medicaid Staff Present: Roberta Capp, M.D., MHS; Paige Clayton, Pharm.D.; Erin Halverson, R.Ph.; Gina Kuebler, R.Ph.; Pam Smith, R.Ph. (via Zoom); and Melissa Biddle.

Managed Care Organization (MCO) Staff Present: Jordan Thoman, Wellpoint Iowa; Emily Rogers, Iowa Total Care; and Candace Jordan, Molina Healthcare of Iowa (via Zoom).

Jason Kruse called the meeting to order.

- I. Jason Kruse asked that each committee and DHHS/Medicaid staff member introduce themselves to the public. Jennifer Doudna made the motion to approve the August minutes, and Fadi Yacoub seconded. The motion passed with no objections. There were no new verbal conflict of interest disclosures. Forms were provided to the committee members so they could complete their annual disclosures. The committee also approved minor changes to the P&T Policies and Procedures, allowing virtual verbal public comment due to a policy change requiring that meetings have a virtual option for public attendance, and updating Medicaid contact email addresses. Fadi Yacoub made the motion to approve the proposed changes, Jennifer Doudna seconded, and all members were in agreement.
- II. PDL Revision Notifications (Erin Halverson): There were no new notifications. The fax blast included in the committee binder by mistake had previously been reviewed at the August meeting.
- III. Drug Rebate Issues (Dr. Clayton): There are no issues to report, but Optum is monitoring the effects and trends of the AMP cap removal effective in January 2024, as PDL changes could arise due to manufacturers' responses to that change. There have been a lot of pricing fluctuations and correcting readjustments as a result, and there will also be product discontinuations. On the third quarter data that just came out last week, things seem to have settled down. Optum staff have been working with manufacturers on supplemental rebates to attempt to bring down costs.

- IV. PA Criteria/Pro-DUR Edits (Dr. Cate): Committee members were provided copies of Informational Letter 2625-MC-FFS-D sent to providers notifying them of Pharmacy Program and PDL changes since the last meeting, including the optional 90-day supply for select medications that went into effect October 1, 2024. The committee also received a copy of the letter sent from the DUR Commission to DHHS following their meeting on November 7th, which had recommended changes to the prior authorization criteria for: Biologicals for Inflammatory Bowel Disease; Janus Kinase Inhibitors; Maralixibat (Livmarli); Omalizumab (Xolair); Oral Glucocorticoids for Duchenne Muscular Dystrophy; Tralokinumab (Adbry); and Zuranolone (Zurzuvae).
- V. Legislation (Dr. Cate): There were no new updates.
- VI. Iowa Medicaid Updates (Dr. Cate): Elizabeth Matney resigned as Medicaid Director effective November 1st, and Rebecca Curtiss is serving as Interim Director while a nationwide search is conducted. A cost of dispensing survey was sent out to providers in May, with responses due back August 14, 2024. Results are being reviewed by HHS leadership, with the intent that the dispensing fee increase be added into the HHS budget request for the next legislative session. Once finalized, the report will be published on the state’s rate setting vendor Myers & Stauffer’s web page and provided to the committee.
- VII. Public Comment: In addition to the written public comments provided to committee members, they heard oral public comment from the speakers shown below. They were also forwarded manufacturer comments as they were received via email prior to the meeting.

Name	Organization / Manufacturer	Product
Chase Williams	Gilead Sciences	Livdelzi
Jasmine Inman	Teva	Uzedy, Simlandi
Shirley Quach	Novartis	Kesimpta
Sajani Barot	Idorsia Pharmaceuticals	Tryvio
Rafik Marouf	Medunik Pharmaceuticals	Pheburane, Siklos
Colleen Stoyas	UCB	Zilbrysq
Ronald DePue	Axsome	Auvelity
Joe Cirrincione	Incyte	Opzelura
Paul Thompson	Alkermes	Aristada, Lybalvi, Vivitrol
Andrea Hawkinson	Recordati Rare Diseases, Inc	Carbaglu
Ray Kong	Neurocrine	Ingrezza
Cambridge Hampsher	Indivior	Sublocade, Opvee
Jennifer Shear	Jazz Pharmaceuticals	Epidiolex
Kalpesh Patel	Astellas	Veozah
Kaj Thompson	Johnson & Johnson	Tremfya
Kevin Saldanha	Mitsubishi Tanabe Pharma America	Radicava
Abigail Hata	Amgen	Ravicti
Christopher Gallardo	Intra-Cellular Therapeutics	Caplyta
Amy Hornig	Abbvie	Qulipta
Brandon Walker	Servier	Voranigo

Member Comments Received: None

Written Provider Comments Received: Gvoke (2 submissions), Caplyta (5 submissions)

Written Manufacturer Comments Received: Gvoke, Isturisa

At 11:30, Jennifer Doudna motioned to go to closed session as authorized by Iowa Code Section 21.5(1)(a) of the Open Meetings Law to review or discuss economic records associated with the PDL which are required or authorized to be kept confidential. Fadi Yacoub seconded, and the motion passed with unanimous roll call approval, minus Tricia McComb who was not present for the roll call. Open session resumed at 1:22.

VIII. PDL Discussion and Deliberation (Erin Halverson): All subsequent recommendations (with numbering as provided on agenda attachment 3) were made to maximize cost savings to the program unless otherwise noted.

1. Levalbuterol nebulization solution to Preferred
2. Asmanex HFA to Preferred
3. Clonazepam ODT to Preferred
4. Lamotrigine ER Tablets to Preferred
5. Levetiracetam ER Tablets to Preferred
6. Epidiolex to Preferred with 12 month electronic lookback for 2 antiepileptic drugs
7. Citalopram 30mg capsules to Non-Preferred
8. Paroxetine oral suspension to Non-Preferred
9. Venlafaxine ER Tablets to Preferred
10. Amoxapine to Non-Preferred
11. Rebinyn to Preferred
12. Elocate to Preferred
13. Altuviiiio to Preferred
14. Adbry to Preferred with Conditions
15. Amjevita 40mg/0.4 mL and 80mg/0.8mL to Preferred with Conditions
16. Yusimry to Preferred with Conditions
17. Adalimumab-fkjp to Preferred with Conditions
18. Tremfya to Preferred with Conditions
19. Skyrizi Subcutaneous (Prefilled Syringe, Auto-Injector, Solution Cartridge) to Preferred with Conditions
20. Rinvoq to Preferred with Conditions
21. Adalimumab-aacf to Preferred with Conditions
22. Adalimumab-adbm to Preferred with Conditions
23. Uzedy to Preferred Step 2
24. Rykindo to Preferred Step 2
25. Tolterodine Tablets to Preferred
26. Myrbetriq Tablets to Preferred
27. Tolterodine ER Capsules to Preferred

28. Opzelura to Preferred with Conditions
29. Hemangeol to Preferred with PA for diagnosis confirmation
30. Felodipine to Preferred
31. Verapamil ER Capsules to Preferred
32. Carnitor tablets to Non-Preferred
33. Levocarnitine tablets to Preferred

Fadi Yacoub motioned to accept the recommendations #1-33 above, and Dawn Schissel seconded. The decision was unanimous.

34. Ubrelvy to Preferred with Conditions
35. Colestipol Oral Granules & Packet to Non-Preferred
36. Prevalite to Preferred
37. Zafemy to Preferred
38. Novolin N FlexPen to Preferred
39. Novolin R FlexPen to Preferred
40. Invokana to Non-Preferred with Conditions
41. Invokamet to Non-Preferred with Conditions
42. Dermotic to Non-Preferred
43. Fluocinolone Acetonide Otic to Preferred
44. Veozah to Preferred
45. Mircera to Preferred with Conditions
46. Retacrit to Non-Preferred with Conditions
47. Bijuva to Preferred
48. Duavee to Preferred
49. Suflave to Preferred
50. Gavilyte-C to Preferred
51. Pertzye to Preferred
52. Emflaza to Preferred with Conditions
53. Fynetra to Non-Preferred with Conditions
54. Fulphila to Preferred with Conditions
55. Sodium polystyrene sulfonate oral powder to Non-Preferred due to risk of adverse events
56. Frovatriptan to Preferred with Conditions
57. Eletriptan to Preferred with Conditions
58. Kesimpta to Preferred
59. Copaxone 20mg/mL to Non-Preferred
60. Zimhi to Preferred
61. Xiidra to Preferred
62. Procentra to Preferred with Conditions
63. Focalin XR to Preferred with Conditions
64. Armour Thyroid to Preferred
65. Niva Thyroid to Preferred
66. NP Thyroid to Preferred
67. Carbaglu to Preferred with PA
68. Xaciato Gel to Preferred
69. Vandazole to Preferred

Fadi Yacoub motioned to accept the recommendations #34-69 above, and Dawn Schissel seconded. The decision was unanimous.

The committee would also like to change Katerzia to Preferred on the PDL. Jason Kruse made the motion for this additional change, and Fadi Yacoub seconded. All members were in favor.

IX. Newly Released Drugs (Dr. Capp and Erin Halverson): All following recommendations (with numbering as provided on agenda attachment 4) were made to maximize cost savings to the program unless otherwise noted. Dr. Capp reviewed the clinical information for the new drugs, and then Erin Halverson read through the recommendations as follows:

1. Iqirvo- Recommend status on the PDL as Non-Preferred
2. Lazcluze- Recommend status on the RDL as Non-Recommended with Conditions (Select Oncology Agents)
3. Livdelzi- Recommend status on the PDL as Non-Preferred
4. Ohtuvayre- Recommend status on the PDL as Non-Preferred
5. Tryvio- Recommend status on the PDL as Non-Preferred
6. Voranigo- Recommend status on the RDL as Non-Recommended with Conditions (Select Oncology Agents)
7. Xolremdi- Recommend status on the PDL as Non-Preferred

Dawn Schissel motioned to accept the recommendations above, with the addition that Tryvio be referred to the DUR Commission to develop prior authorization criteria that better defines use for resistant hypertension. Fadi Yacoub seconded, and the decision was unanimous.

X. Newly Released Generic Drugs and New Drug Dosage Forms/Strengths/Combinations/BioSimilar (Erin Halverson): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
Dasatinib	Non-Preferred with Conditions
Ivabradine	Non-Preferred with Conditions
L-glutamine	Non-Preferred
Liraglutide	Non-Preferred with Conditions
Lofexidine	Non-Preferred
Oxcarbazepine ER	Non-Preferred with Conditions

Drug Name	PDL/RDL Recommendation
Adalimumab-aaty	Non-Preferred with Conditions
Crexont	Non-Preferred with Conditions
Entresto Sprinkle Caps	Non-Preferred with Conditions
Onyda XR	Non-Preferred

Simlandi	Preferred with Conditions
Sitagliptin / Metformin	Non-Preferred with Conditions
Tyenne Subcutaneous Solution (Auto-Injector & Prefilled Syringe)	Preferred with Conditions
Vigafyde	Non-Preferred

Fadi Yacoub motioned to accept the recommendations in both tables above. Dawn Schissel seconded, and all members were in favor.

A motion was made by Fadi Yacoub to adjourn the meeting. It was seconded by Dawn Schissel, and all in attendance approved. The meeting adjourned at 1:42 p.m. The next scheduled meeting is set for April 17, 2025.